<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE NewsML PUBLIC "urn:newsml:iptc.org:20001006:NewsMLv1.0:1" "http://www.comtexnews.net/newsmlresources/NewsMLv1.0.dtd" [
<!ENTITY % nitf SYSTEM "http://www.comtexnews.net/newsmlresources/nitf-2-5.dtd">
%nitf;
]>
  <NewsML><Catalog><Resource><Urn>
urn:newsml:comtexnews.net:20010201:ComtexStatus
</Urn><DefaultVocabularyFor Context="Status" /></Resource><Resource><Urn>
urn:newsml:comtexnews.net:20010201:Delivery:1
</Urn><DefaultVocabularyFor Context="SentFrom" /></Resource><Resource><Urn>
urn:newsml:comtexnews.net:20010201:NewsService:1
</Urn><DefaultVocabularyFor Context="NewsService" /></Resource><Resource><Urn>
urn:newsml:comtexnews.net:20010201:NewsProduct:1
</Urn><DefaultVocabularyFor Context="NewsProduct" /></Resource><Resource><Urn>
urn:newsml:iptc.org:20001006:IptcRoleTypes
</Urn><DefaultVocabularyFor Context="Role" /></Resource><Resource><Urn>
urn:newsml:iptc.org:20001006:IptcNewsItemTypes
</Urn><DefaultVocabularyFor Context="NewsItemType" /></Resource><Resource><Urn>
urn:newsml:iptc.org:20001006:IptcMimeTypes
</Urn><DefaultVocabularyFor Context="MimeType" /></Resource><Resource><Urn>
urn:newsml:iptc.org:20001006:IptcMediaTypes
</Urn><DefaultVocabularyFor Context="MediaType" /></Resource><Resource><Urn>
urn:newsml:iptc.org:20001006:IptcPriority
</Urn><DefaultVocabularyFor Context="Priority" /></Resource><Resource><Urn>
urn:newsml:iptc.org:20001006:IptcUrgency
</Urn><DefaultVocabularyFor Context="Urgency" /></Resource><Resource><Urn>
urn:newsml:iptc.org:20001006:Languages
</Urn><DefaultVocabularyFor Context="Language" /></Resource></Catalog><NewsEnvelope><TransmissionId>260616286</TransmissionId><SentFrom><Party FormalName="Comtex" /></SentFrom><DateAndTime>20161003T111219</DateAndTime><NewsService FormalName="Comtex" /><NewsProduct FormalName="!BUSINESS&#xA;" /><NewsProduct FormalName="!bzx&#xA;" /><NewsProduct FormalName="!COMMUNITY&#xA;" /><NewsProduct FormalName="!hedge+funds&#xA;" /><NewsProduct FormalName="!iapws&#xA;" /><NewsProduct FormalName="!PUBCO+SELECT&#xA;" /><NewsProduct FormalName="!PUBLIC+COMPANIES&#xA;" /><NewsProduct FormalName="!WALL+STREET&#xA;" /><Priority FormalName="5" /></NewsEnvelope><NewsItem><Identification><NewsIdentifier><ProviderId>comtexnews.net
</ProviderId><DateId>20161003</DateId><NewsItemId>277b3002</NewsItemId><RevisionId PreviousRevision="0" Update="N">
1
</RevisionId><PublicIdentifier>urn:newsml:comtexnews.net:20161003:277b3002:1</PublicIdentifier></NewsIdentifier></Identification><NewsManagement><NewsItemType FormalName="News" /><FirstCreated>20161003T111219</FirstCreated><ThisRevisionCreated>20161003T111219</ThisRevisionCreated><Status Vocabulary="urn:newsml:comtexnews.net:20010101:ComtexStatus:1" Scheme="ComtexStatus" FormalName="Usable" /><Urgency FormalName="5" /></NewsManagement><NewsComponent><Role FormalName="Logo" /><NewsLines><NewsLine><NewsLineType FormalName="ClickThru URL" /><NewsLineText>http://www.rosenlegal.com/cases-960.html
</NewsLineText></NewsLine></NewsLines><ContentItem Duid="c71505133" Href="http://mms.businesswire.com/media/20161003006075/en/527137/2/Rosen-Law_Logo_-_Golden.jpg"><Format FormalName="JPEG Baseline" /><MimeType FormalName="image/jpeg" /><Characteristics><SizeInBytes>9689
</SizeInBytes><Property FormalName="ImageUse" Value="Thumbnail" /><Property FormalName="PixelWidth" Value="120" /><Property FormalName="PixelHeight" Value="58" /></Characteristics></ContentItem><ContentItem Duid="c71505134" Href="http://mms.businesswire.com/media/20161003006075/en/527137/21/Rosen-Law_Logo_-_Golden.jpg"><Format FormalName="JPEG Baseline" /><MimeType FormalName="image/jpeg" /><Characteristics><SizeInBytes>13530
</SizeInBytes><Property FormalName="ImageUse" Value="Square" /><Property FormalName="PixelWidth" Value="150" /><Property FormalName="PixelHeight" Value="150" /></Characteristics></ContentItem></NewsComponent><NewsComponent><NewsLines><NewsLine><NewsLineType FormalName="ClickThru URL" /><NewsLineText>http://www.rosenlegal.com/cases-960.html
</NewsLineText></NewsLine></NewsLines></NewsComponent><NewsComponent Essential="yes" EquivalentsList="no"><Role FormalName="Main" /><NewsLines><HeadLine><b>EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities 
      Claims Against Fusion Pharm, Inc. </b></HeadLine><DateLine>NEW YORK, Oct 03, 2016 (BUSINESS WIRE) --
</DateLine><CopyrightLine>Copyright Business Wire 2016
</CopyrightLine><SlugLine>NY-ROSEN-LAW-FIRM
</SlugLine><KeywordLine xml:lang="en">advertising
<Origin AssignedBy="Comtex" /></KeywordLine><KeywordLine xml:lang="en">business
<Origin AssignedBy="Comtex" /></KeywordLine><KeywordLine xml:lang="en">ceo
<Origin AssignedBy="Comtex" /></KeywordLine><KeywordLine xml:lang="en">email
<Origin AssignedBy="Comtex" /></KeywordLine><KeywordLine xml:lang="en">equity
<Origin AssignedBy="Comtex" /></KeywordLine><KeywordLine xml:lang="en">investigation
<Origin AssignedBy="Comtex" /></KeywordLine><KeywordLine xml:lang="en">law
<Origin AssignedBy="Comtex" /></KeywordLine><KeywordLine xml:lang="en">lawsuit
<Origin AssignedBy="Comtex" /></KeywordLine><KeywordLine xml:lang="en">money
<Origin AssignedBy="Comtex" /></KeywordLine><KeywordLine xml:lang="en">otc
<Origin AssignedBy="Comtex" /></KeywordLine><KeywordLine xml:lang="en">sales
<Origin AssignedBy="Comtex" /></KeywordLine><KeywordLine xml:lang="en">securities
<Origin AssignedBy="Comtex" /></KeywordLine></NewsLines><AdministrativeMetadata><Catalog><Resource><Urn>
urn:newsml:comtexnews.net:20010201:Providers:1
</Urn><DefaultVocabularyFor Context="Provider/Party" /></Resource><Resource><Urn>
urn:newsml:comtexnews.net:20010201:Source:1
</Urn><DefaultVocabularyFor Context="Source/Party" /></Resource><Resource><Urn>
urn:newsml:comtexnews.net:20010201:SourceProperties:1
</Urn><DefaultVocabularyFor Context="Property" /></Resource></Catalog><FileName>260616286.xml</FileName><Provider><Party FormalName="Comtex" /></Provider><Source><Party FormalName="BusinessWire - BZX" /></Source><Property FormalName="SourceCode" Value="BZX" /></AdministrativeMetadata><RightsMetadata><Copyright><CopyrightHolder>Copyright Business Wire 2016
</CopyrightHolder><CopyrightDate>2016</CopyrightDate></Copyright></RightsMetadata><DescriptiveMetadata><Language FormalName="en" /><Property FormalName="PublicCompany" Vocabulary="urn:newsml:comtexnews.net:20010201:DomesticPublicCompanies:1"><Property FormalName="CompanyName" Value="Fusion Pharm Inc" /><Property FormalName="StockSymbol" Value="FSPM" /><Property FormalName="StockExchange" Value="OTC US" /><Property FormalName="SICCode" Value="N/A" /><Property FormalName="CUSIP" Value="36113H100" /><Property FormalName="SEDOL" Value="N.S." /><Property FormalName="ISINNumber" Value="US36113H1005" /><Property FormalName="MarketStatus" Value="ACTV" /><Property FormalName="SecurityType" Value="Common Stock" /><Property FormalName="Country" Value="UNITED STATES" /><Property FormalName="IndustryGroup" Value="Healthcare-Products" /><Property FormalName="IndustrySubGroup" Value="Medical Products" /><Property FormalName="IndustrySector" Value="Consumer, Non-cyclical" /></Property></DescriptiveMetadata><ContentItem><Comment>
Main
</Comment><MediaType FormalName="Text" /><MimeType FormalName="text/vnd.IPTC.NITF" /><DataContent><head><meta name="BZX:StockSymbol" content="OTCBB:FSPM" /></head><body><body.head><distributor>BusinessWire - BZX</distributor></body.head><body.content><p>Rosen Law Firm, a global investor rights law firm, announces it is 
      investigating potential securities claims on behalf of shareholders of 
      Fusion Pharm, Inc. (OTC: FSPM) resulting from allegations that Fusion 
      Pharm may have issued materially misleading business information to the 
      investing public.
</p><p>On September 16, 2016, the SEC announced fraud charges against Fusion 
      Pharm and its CEO, Scott M. Dittman, among others, for misleading 
      investors by recording and trumpeting revenues for purported sales of 
      PharmPods by round-tripping money from illegal stock sales by hidden 
      affiliates.
</p><p>Rosen Law Firm is preparing a class action lawsuit to recover losses 
      suffered by Fusion Pharm investors. If you purchased shares of Fusion 
      Pharm on or before September 16, 2016, please visit the firm&#x2019;s website 
      at <a href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.rosenlegal.com%2Fcases-960.html&amp;esheet=51431835&amp;newsitemid=20161003006075&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.rosenlegal.com%2Fcases-960.html&amp;index=1&amp;md5=7dd7b80ff51e106e83631b5e2d15b4ef" rel="nofollow">http://www.rosenlegal.com/cases-960.html</a> 
      for more information. You may also contact Phillip Kim or Kevin Chan of 
      Rosen Law Firm toll free at 866-767-3653 or via email at <a href="mailto:pkim@rosenlegal.com" rel="nofollow">pkim@rosenlegal.com</a> 
      or <a href="mailto:kchan@rosenlegal.com" rel="nofollow">kchan@rosenlegal.com</a>.
</p><p>Follow us for updates on LinkedIn: <a href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm&amp;esheet=51431835&amp;newsitemid=20161003006075&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm&amp;index=2&amp;md5=9820f4d09569f38e97a2f9a358f81181" rel="nofollow">https://www.linkedin.com/company/the-rosen-law-firm</a> 
      or on Twitter: <a href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Frosen_firm&amp;esheet=51431835&amp;newsitemid=20161003006075&amp;lan=en-US&amp;anchor=https%3A%2F%2Ftwitter.com%2Frosen_firm&amp;index=3&amp;md5=48870ad42792b593618fc531a8c0980a" rel="nofollow">https://twitter.com/rosen_firm</a>.
</p><p>Rosen Law Firm represents investors throughout the globe, concentrating 
      its practice in securities class actions and shareholder derivative 
      litigation.
</p><p>Attorney Advertising. Prior results do not guarantee a similar outcome.
</p><p><img alt="" src="http://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20161003006075r1&amp;sid=cmtx5&amp;distro=nx&amp;lang=en"/><span class="bwct31415"/>
</p><p><span id="mmgallerylink-phrase">View source version on businesswire.com: </span><span id="mmgallerylink-link"><a href="http://www.businesswire.com/news/home/20161003006075/en/" rel="nofollow">http://www.businesswire.com/news/home/20161003006075/en/</a></span>
</p><p>SOURCE: Rosen Law Firm
</p><pre>The Rosen Law Firm, P.A.<br/>Laurence Rosen, Esq.<br/>Phillip Kim, Esq.<br/>Kevin 
      Chan, Esq.<br/>275 Madison Avenue, 34<sup>th</sup> Floor<br/>New York, 
      NY 10016<br/>Tel: 212-686-1060<br/>Toll Free: 866-767-3653<br/>Fax: 
      212-202-3827<br/><a href="mailto:lrosen@rosenlegal.com">lrosen@rosenlegal.com</a><br/><a href="mailto:pkim@rosenlegal.com">pkim@rosenlegal.com</a><br/><a href="mailto:kchan@rosenlegal.com">kchan@rosenlegal.com</a><br/><a href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.rosenlegal.com&amp;esheet=51431835&amp;lan=en-US&amp;anchor=www.rosenlegal.com&amp;index=4&amp;md5=8bf9f347dd53e3dddabecc005229e195">www.rosenlegal.com</a>
</pre></body.content></body></DataContent></ContentItem></NewsComponent></NewsItem></NewsML>